Health Economics›Esophageal squamous cell carcinoma›Metastatic or locally advanced disease subsequent lines of therapy

Metastatic or locally advanced disease subsequent lines of therapy

Esophageal squamous cell carcinoma · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	9.3 mo	—	—	1
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	—	7.4 mo	—	—	4
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	6.7 mo	—	—	5
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	—	6.3 mo	—	—	3
Camrelizumab monotherapy Variant #01 Partial	—	—	14d	—	8.0 mo	—	—	1
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	11.0 mo	—	—	2
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	8.6 mo	—	—	1

7 of 7 regimens shown